Clinical trial · Observational
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel
Observational Study on Perception of Information and Quality of Life in Neuroendocrine Tumor on Lanreotide Autogel
NCT03562091CI-TRIAL-00046853OPERAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate, in standard practice, the change in information received and perceived by the patient, extension of the disease and its treatment. These parameters will be evaluated by means of validated self-administered questionnaires that can be used in standard practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Absolute variation on the score (standardized on a scale from 0 to 100) of the 3 targeted dimensions (disease, treatments and supportive care) of the self-administered Quality of Life Questionnaire (QLQ) QLQINFO25
- timeFrame
- Change from Baseline to Month 6
Secondary outcomes (6)
- measure
- Change from baseline to Month 3 of the 3 targeted dimensions (disease, treatments and supportive care (ie, other services)) of QLQ-INFO25 self-administered questionnaire
- timeFrame
- Change from Baseline to Month 3
- measure
- Changes from baseline to Month 3 and Month 6 on dimensions of the QLQ-INFO25 self-administered questionnaire not part of the primary endpoint
- timeFrame
- Change from Baseline to Month 3 and 6
- measure
- Change from baseline to Month 3 and Month 6 in quality of life using QLQ-C30 questionnaire
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Gastroenteropancreatic neuroendocrine tumor (GEPNET), histologically proven, grade 1 or 2, * Subject eligible for antitumor treatment initiation with lanreotide autogel\*, alone or combined with other therapies, selected freely and prior to inclusion in the study by the physician, * Subject able to complete a self-administered evaluation questionnaire during initiation visit and liable to be seen again within 6 months of the initial visit based on the physician's usual practices * Having consented in writing to his/her data being accessed for participation in the study. Exclusion Criteria: * Previously treated by lanreotide autogel * Simultaneously participating in a clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.